18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
Not Applicable
- Conditions
- Lymphoma, T-Cell, Peripheral
- Interventions
- Device: 18F-FDG PET/ CT
- Registration Number
- NCT03051581
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Brief Summary
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of PTCL can predict disease progression
- Detailed Description
In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in PTCL.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- newly diagnosed PTCL
- treated using an anthracycline-containing regimen
- minimal follow-up at 6 months after the completion of first-line treatment
- complete medical history and clinicopathological data
Exclusion Criteria
- secondary malignant disease
- serious infection or inflammation (e.g., HIV)
- primary central nervous system lymphoma
- hepatic or renal dysfunction.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 18F-FDG PET/CT-based prognostic model of PTCL 18F-FDG PET/ CT The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
- Primary Outcome Measures
Name Time Method 3 year progression-free survival up to 3 years after initial diagnosis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking University Cancer Hospital
🇨🇳Beijing, Beijing, China